state smoking laws, 21:27-28

LEUKEMIA
(See also NEOPLASMS)
benezene and, 14:51

LEUKOCYTES
- cell count in cigar and pipe smokers, 12:81
- cell count in ex-smokers, 12:81
- cell count in smokers vs. nonsmokers, 12:79-82
- chemotaxis in smokers vs. nonsmokers, 12:82
- effect of inhalation and smoking levels on cell count, 79-82
- granular, levels in smokers, 10:20

LEUKOPLAKIA
(See also MOUTH NEOPLASMS)
bettel chewing and, 5:41
bidi smoking and, 5:41
snuff in etiology of, 13:40
 tobacco chewing and, 5:41
 tobacco chewing in etiology of, 13:40-41

LIFE EXPECTANCY
(See also MORTALITY)
definition, 2:11
effect of smoking levels in the United States, 2:12

LIFE SKILLS TRAINING
- antismoking education component, 20:11

LIP NEOPLASMS
(See also MOUTH NEOPLASMS)
- alcohol consumption and smoking and, 5:41
- pipe smoking and, 1:27
- pipe smoking in etiology of, 13:21
- relative risk in cigarette vs. cigar vs. pipe smokers, 13:22

LIPIDS
- effect of smoking on metabolism, 12:65

LIVER
- function, effect of aromatic hydrocarbons, 12:7-8
- organ weight in smokers vs. nonsmokers, 12:9

LOBELINE
- nicotine substitute, 19:16-17

LOCUS OF CONTROL
- academic achievement and, 20:22
  cessation of smoking and, 18:18
  maintenance of smoking and, 18:9

Low-tar cigarettes
- See CIGARETTES, LOW-TAR

Lung diseases
- See BRONCHOPULMONARY DISEASES; BYSSINOSIS; CHRONIC OBSTRUCTIVE LUNG DISEASES; RESPIRATORY TRACT DISEASES

LUNG FUNCTION
(See also RESPIRATORY FUNCTION TESTS)
effect of carbon monoxide exposure, 11:27-28
effect of cessation of smoking, 6:22-23
effect of cigar smoking, 13:34-35, 13:38
effect of nicotine, 14:90
effect of passive smoking in asthmatic patients, 10:22
effect of pipe smoking, 13:34-35, 13:38
effect of smoking, 6:22, 14:90
effect of smoking, summary of findings, 1:18
effect of smoking levels, 6:22
sex ratio, 6:21-22
in smokers vs. nonsmokers, 6:21
in smokers vs. nonsmokers vs. ex-smokers, 6:23
smoking in chlorine workers and, 7:10
smoking in coal miners and, 7:9
smoking in cotton workers and, 7:9
in white, black and oriental smoking and nonsmoking men and women, 6:21

LUNG NEOPLASMS
(See also BRONCHIAL NEOPLASMS; RESPIRATORY TRACT NEOPLASMS)
air pollution in etiology of, 5:25-27
animal models, 5:29-31
aryl hydrocarbon hydroxylase inducibility and, 5:57
arsenosts and smoking in etiology of, 5:28
carcinoembryonic antigen test in diagnosis of, 12:61
chloromethyl ethers and smoking in etiology of, 5:29
in chloromethyl ether workers, 7:16

cigar and pipe smoking and, summary of findings, 1:28

cigar smoking in etiology of, 13:28

effect of age began smoking on mortality ratio, 13:14

effect of cessation of smoking on risk and mortality ratios, 5:24-26

effect of filtered vs. unfiltered cigarettes on risk, 5:16, 5:18-19

effect of inhalation on mortality ratio, 5:14-15

effect of low tar and nicotine cigarettes on mortality ratio, 5:15-17

effect of smoking levels on mortality ratio, 5:13

effect of smoking levels on risk, 5:12-13, 5:16, 5:18-19

effect of smoking on histologic type, 5:22-24

effect of smoking on mortality rates, 5:9-11

heredity and, 5:23

histologic types, 5:20-24

induced by benzo(e)pyrene in hamsters, 5:30

induced by nitrosamines in animals, 5:30

mortality in asbestos workers, 7:11-12

mortality rates in cigar vs. pipe smokers, 5:23

mortality rates in women, 5:16-18, 5:20-
mortality ratio in cigar vs. cigarette vs. pipe smokers, 13:26

mortality rate trends in Great Britain and the United States, 5:10-11

mortality ratio in smokers vs. nonsmokers, 5:11-12

nickel and smoking in etiology of, 5:28

occupational exposures and smoking in etiology of, 5:27-29, 7:17

relative risk in cigar vs. cigarette vs. pipe smokers, 13:29-30

role of pulmonary alveolar macrophages, 5:31

smoking and, summary of findings, 1:16

smoking and occupational risk in whites and nonwhites, 7:17

smoking in asbestos workers and, 7:11-13

smoking in etiology of, historical perspective, 5:9

smoking in uranium miners and, 7:14

in smoking vs. nonsmoking twins, 5:28

uranium and smoking in etiology of, 5:28

in urban vs. rural areas, 5:25-27

LUNGS

(See also RESPIRATORY SYSTEM)

air pollution and pathology in smokers vs. nonsmokers, 6:36

effect of cigar smoking, 13:35

effect of pipe smoking, 13:35

effect of smoke inhalation in dogs, 14:76

effect of smoke inhalation in monkeys, 14:76

effect of smoking, 6:18

effect of smoking, summary of findings, 1:18-19

effect of smoking levels on pathology, 6:24-27

effect of smoking on pathogenesis, 6:25-26

enzyme induction of emphysema, 6:28

nicotine absorption, 14:85

organ weight in smokers vs. nonsmokers, 12:9

LYMPOSOCYTES

B and T in smokers vs. nonsmokers, 6:31

effect of smoking, 10:19

effect of tobacco smoke in mice, 10:19

effect of tobacco smoke on immune function, 10:17

MACROPHAGES, ALVEOLAR

(See also PHAGOCYTOSIS)

in bronchial fluid of smokers, 6:28

count in smokers vs. nonsmokers, 6:29

effect of cigarette smoke, 6:29-30

effect of cigarette smoke on phagocytic activity, 10:17

effect of tobacco smoke, 10:15-16

effect of tobacco smoke on count and ultrastructure, 10:16
effect of smoke inhalation in dogs, 14:76
effect of smoke inhalation in monkeys, 14:76
elastase release in smokers vs. nonsmokers, 6:30
in lung neoplasm etiology, 5:31
proteinase activity in smokers vs. nonsmokers, 6:29
in smokers vs. nonsmokers, 6:31
Mainstream smoke
See SMOKE, CIGARETTE MAINSTREAM; SMOKE STREAMS
MALEIC HYDRAZIDE
hydrazine levels and, 14:41
structural formula, 14:62
tobacco curing and, 14:47
MALES
(See also SEX RATIO)
smoking prevalence, A:11, A:12-13, A:17-18
MARIJUANA
(See also CANNABIS, DRUG ABUSE)
correlation with tobacco smoking, 18:14
effect on enzyme activity, 12:42-43
effect on pharmacokinetics, 12:42-43
effect on pregnant animals, 8:53
MATERNAL-FETAL EXCHANGE
aromatic hydrocarbons in animals, 8:66
benzo(a)pyrene in animals, 8:66
carbon monoxide in sheep, 8:59
carbon monoxide in sheep and dogs, 8:58
nicotine in animals, 8:54
Maternal smoking
See SMOKING, MATERNAL
Maximum mid-expiratory flow rate measurements
See RESPIRATORY FUNCTION TESTS
MECAMYLAMINE
nicotine antagonist, 16:3-9
MEDICAL STUDENTS
antismoking education, 22:17-18
perceptions of physicians' smoking habits, 22:7
smoking habits, 18:8, 22:18
MEDITATION
in modification of smoking behavior, 19:22
Men
See MALES
MEPERIDINE
total clearance in smokers vs. nonsmokers, 12:39
MEPROBAMATE
cessation aid, 19:17
MERCURY
(See also METALS)
levels in smokers vs. nonsmokers, 12:73
smoking and occupational exposure, 7:7
MESOTHELIOMA
(See also CARCINOGENESIS; NEOPLASMS)
smoking and asbestos exposure and, 7:12
METABOLISM
(See also NICOTINE METABOLISM)
carbon monoxide in maintenance of smoking habit, 15:17
effect of smoking on carbohydrates, lipids and proteins, 12:65
effect of tobacco smoke on food constituents and additives, 12:75-76
nicotine in maintenance of smoking habit, 15:16
nicotine, in smokers vs. nonsmokers, 15:9
tar, in maintenance of smoking habit, 15:17
METALS
(See also CADMIUM; CALCIUM; LEAD; MERCURY; NICKEL)
cardiovascular diseases and, 4:62
in cigarette smoke as carcinogens, 14:59-60
levels in particulate phase cigarette smoke, 14:59
levels in smokers vs. nonsmokers, 12:73-74
in tobacco smoke, 14:58-59
METHYL PARATHION
smoking and occupational exposure, 7:7
METHYLCHOLANTHRENE
(See also AROMATIC HYDROCARBONS)
effect on aryl hydrocarbon hydroxylase activity in rats, 12:28-29
effect on enzyme activity, 12:21-22
effect on phenacetin pharmacokinetics in rats, 12:28-29
effect on RNA metabolism, 12:21-22
effect on theophylline metabolism in rats, 12:32
in oral neoplasm induction in hamsters, 5:42

METHYLENE CHLORIDE
occupational hazards, 7:8-9

MORBIDITY
(See also MORTALITY)
bed disability in smokers vs. non-smokers, 3:12
bronchitis and emphysema in the United States, 6:20
coronary heart disease in ex-smokers, 4:38
effect of cessation of smoking, summary of findings, 1:12-13
effect of smoking, 3:5
effect of smoking, summary of findings, 1:12-13
effect of smoking on acute conditions, 3:6
effect of smoking on chronic conditions, 3:6-7
findings of NCHS National Health Interview Survey, 1:12-13
incidence of acute conditions in smokers vs. non-smokers vs. ex-smokers, 3:9
peptic ulcer in the United States, 9:17
prevalence rate of chronic conditions, 3:6-7
smoking and lung neoplasms and occupational risk, 7:17
work-days lost, 3:8-9

MORBIDITY RATIO
angina pectoris, effect of smoking levels, 4:48
coronary heart disease in ex-smokers, 4:28-31, 4:34-35
coronary heart disease in smokers vs. non-smokers, 4:27-30, 4:30-37

MORTALITY
(See also EXCESS DEATHS; FETAL MORTALITY; INFANT MORTALITY; LIFE EXPECTANCY; MORBIDITY, PERINATAL MORTALITY)
annual probability of dying in smokers vs. nonsmokers vs. ex-smokers, 2:30-34
bronchitis in cigar vs. cigarette vs. pipe smokers, 13:34
chronic obstructive lung disease in smokers, 2:41, 6:9
chronic obstructive lung disease in smokers vs. nonsmokers vs. ex-smokers, 6:10
cigar and pipe smokers vs. ex-smokers, 13:9
cigar vs. cigarette vs. pipe smokers, 13:13-14
effect of age began smoking, 2:19
effect of cigar smoking, 2:30, 2:35-37
effect of environmental factors, 2:42
effect of heredity in smoking related disease, 2:41-42
effect of inhalation, 2:20
effect of inhalation in cigar and pipe smokers, 13:18
effect of nicotine and tar content, 2:22
effect of pipe smoking, 2:30, 2:35-37
effect of smoking in the United States, 2:9
effect of smoking in women, 2:25
effect of smoking levels in cigar and pipe smokers, 13:14-16
effect of social factors, 2:42
effect of years since quitting in ex-smokers, 2:27-34, 2:35
emphysema in cigar vs. cigarette vs. pipe smokers, 13:34
epidemiological studies, 2:12-15
esophageal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:24
ex-smokers, 2:26-30
methods of measuring, 2:10-11
peptic ulcer in cigar vs. cigarette vs. pipe smokers, 13:38
peptic ulcer in smokers, 2:41, 9:10
peptic ulcer in smokers vs. non-smokers, 9:17
respiratory tract infections in smokers, 2:41
risk from pregnancy and childbirth vs. oral contraceptive use, 12:52
smoking and lung neoplasms and asbestos exposure, 7:11

MORTALITY RATES
age groups in the United States, 2:11
cerebrovascular disease in male vs. female smokers, 4:51
circulatory diseases, effect of oral contraceptives and smoking, 12:51
coronary heart disease in ex-smokers, 4:38
definition, 2:10-11
effect of cigar and pipe smoking, summary of findings, 1:27
effect of less hazardous cigarettes, 2:25
lung neoplasms and smoking, summary of findings, 1:16
lung neoplasms, effect of smoking, 5:9-11
lung neoplasms in cigar and pipe smokers, 5:23
lung neoplasms in women, 5:16-18, 5:20
lung neoplasms, trends in Great Britain and the United States, 5:10-11
myocardial infarct in smokers vs. nonsmokers, 4:35-36
smokers vs. nonsmokers, 2:15
thrombosis in smokers vs. nonsmokers, 4:59

MORTALITY RATIO
age groups in the United States, 2:11, 2:17-18
age groups worldwide, 2:17-18
aortic aneurysm, effect of smoking levels, 4:55
bladder neoplasms in smokers, 5:45-46
cardiovascular diseases in cigar vs. cigarette vs. pipe smokers, 13:33-34
cardiovascular diseases in smokers, 2:29
cardiovascular diseases in smokers vs. nonsmokers in Japan, 4:21, 4:34-35
cause-specific, effect of smoking, 2:37-41
cerebrovascular disease in cigar vs. cigarette vs. pipe smokers, 13:33
cerebrovascular disease in male vs. female smokers, 4:51
chronic obstructive lung disease, 6:10
chronic obstructive lung disease in cigar vs. cigarette vs. pipe smokers, 13:35
cigar vs. cigarette vs. pipe smokers, 2:30, 2:35-36
cigarette vs. cigarette vs. pipe vs. mixed smokers, 13:14
coronary heart disease in cigar vs. cigarette vs. pipe smokers, 13:33-34
coronary heart disease in smokers, 2:39
coronary heart disease in ex-smokers, 4:34-35
coronary heart disease in smokers vs. nonsmokers, 4:22-26, 4:36-37
definition, 2:10
effect of age began smoking, 2:19-22
effect of the age of smoking, 4:11-12
effect of combined tobacco product use, 2:90
effect of inhalation, 2:22-24
effect of inhalation, smoking duration and smoking levels in women, 2:26-27
effect of less hazardous cigarettes, 1:11, 2:23-25
effect of reasons for quitting in ex-smokers, 2:27-29
effect of smoking, summary of findings, 1:10-12
effect of smoking duration, 2:17-19
effect of smoking duration in cigar smokers, 2:37
effect of smoking duration in ex-smokers, 2:28-29
effect of smoking duration in pipe smokers, 2:38
effect of smoking levels, 2:15-18, 2:22
effect of smoking levels in cigar smokers, 13:15-17, 2:36-37
effect of smoking levels in ex-smokers, 2:28-29
effect of smoking levels in pipe smokers, 2:36-38, 13:15-17
esophageal neoplasms in cigar and pipe smokers, 5:43
esophageal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:25
esophageal neoplasms in smokers, 5:42-43
ex-smokers, 2:35
kidney neoplasms in smokers, 5:48-49
laryngeal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:24
laryngeal neoplasms in smokers, 5:32-33
lung neoplasms, effect of age began smoking, 5:13-14
lung neoplasms, effect of cessation of smoking, 5:24-26
lung neoplasms, effect of inhalation, 5:14-15
lung neoplasms, effect of low tar and nicotine cigarettes, 5:15-17
lung neoplasms, effect of smoking levels, 5:13
lung neoplasms in cigar vs. cigarette vs. pipe smokers, 13:26-28
lung neoplasms in smokers vs. non-smokers, 5:11-12
lung neoplasms in smoking woman, 5:20-22
neoplasms, effect of cigar and pipe smoking, 13:20
neoplasms in smokers, 2:38
oral neoplasms in cigar vs. cigarette vs. pipe smokers, 13:21-23
oral neoplasms in smokers, 5:39-40
pancreatic neoplasms in smokers, 5:50-52
pharyngeal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:23
in smoking twins, 2:42
sudden cardiac death, effect of smoking levels, 4:45
MORTALITY RISK
infant, and gestational age in smoking vs. non-smoking mothers, 8:43, 8:46
infant, effect of maternal smoking, age, parity, and education, 8:33
infant, effect of maternal smoking, age, parity, and social class, 8:81
infant, synergism of maternal smoking and other risk factors, 8:35
infants of smokers vs. non-smokers, 8:34
MOTIVATION
(See also BEHAVIOR)
cessation of smoking and, 18:19-20
emotional influences in smoking behavior, 16:6
maintenance of smoking and, 18:10-13, 18:15-17
smoking habit in developing countries and, 18:24
smoking habit in the Solomon Islands and, 18:24
MOUTH
nicotine absorption, 14:85
MOUTH MUCOSA
(See also LEUKOPLAKIA)
effect of snuff in women, 13:39-40
MOUTH NEOPLASMS
(See also LEUKOPLAKIA; LIP NEOPLASMS; TONGUE NEOPLASMS)
alcohol consumption and smoking and, 5:40-41
cigar and pipe smoking and, summary of findings, 1:27
MUCOCILIARY SYSTEM
(See also CHLAMYDIAL ACTIVITY; CHLAMYDIAL TOXICITY)
effect of cigarette smoke, 6:32-33, 10:15
MULTICOMPONENT TREATMENT
(See also cessation of smoking)
in cessation of smoking, 16:16-17, 16:19
evaluation, 19:36
modification of smoking behavior, 19:27-28
self-administered, 19:29
MULTIPLE RISK FACTOR INTERVENTION TRIAL
effect on cessation of smoking, 19:15
MUTAGENS
in atherosclerosis etiology, 4:10
MYOCARDIAL INFARCT
(See also CORONARY HEART DISEASE)
animal models, 4:20
atherosclerosis in etiology of, 4:19-20
cessation of smoking after, 19:14
effect of oral contraceptives and smoking on risk, 4:60
effect of smoke inhalation in dogs, 14:77
effect of smoking on risk of recurrence or death, 4:37-38
estrogens and smoking and, 12:52
ex-smokers, 4:21
ischemia and, 4:19-20, 4:39-40
morbidity ratios in ex-smokers, 4:34
morbidity ratios in smokers vs. non-smokers, 4:27-33
oral contraceptives and smoking and, 4:35, 12:51-52
pathogenesis, 4:18-20
research needs, 4:40-41
risk factors, 4:20-21
smokers vs. nonsmokers, 4:35-36
smoking in etiology of, 4:21, 4:38-40
smoking vs. nonsmoking women, 12:52
sudden cardiac death and, 4:43

**MYOCARDIUM**
effect of hypoxia and ischemia, 4:19-20

**NAPHTHALENE**
in cigarette smoke, 14:51
tobacco pyrolysis and, 14:49

**NAPHTHYLAMINES**
(See also AROMATIC AMINES)
pancreatic neoplasms and, 5:51

**NATIONAL ASSOCIATION OF SECONDARY SCHOOL PRINCIPALS**
statement on school smoking policies, 23:8, 23:11, 23:13

**NATIONAL CANCER INSTITUTE**
funding of "Know Your Body" Program, 21:20

**NATIONAL CENTER FOR HEALTH STATISTICS, 3:5**
findings of National Health Interview Survey, 1:12-13
Health and Nutrition Examination Survey, 3:11-12
Health Interview Survey, 3:8-18

**NATIONAL CLEARINGHOUSE FOR SMOKING AND HEALTH**
definition of smokers and nonsmokers, 23:24
establishment of San Diego Community Laboratory, 20:14
Health Consequences of Smoking reports, 1:9-10
smoking prevalence in adults by educational level, A:14-16
smoking prevalence in adults by family income, A:14-16
survey of adolescent smoking, 17:7-8
survey of adult tobacco use, 18:19, 22:6
survey of cigar and pipe smoking in the United States, 13:8-9
survey of smoking attitudes of health professionals, 22:7
survey of smoking habits of health professionals, 22:12-13
survey of tar and nicotine levels of cigarette brands, 3:11
survey of teenage smoking, A:14
training of health educators, 23:32

**NATIONAL INSTITUTES OF HEALTH**
respiratory disease study, 17:15

**NATIONAL INTERAGENCY COUNCIL ON SMOKING AND HEALTH**
funding of youth antismoking projects, 20:24
research guidelines, 19:5-8, 21:16-17

**NATIONAL PARENT-TEACHER ASSOCIATION**
health education programs, 21:21, 21:26

**NEONATAL MORTALITY**
(See also INFANT MORTALITY; MORTALITY RISK; PERINATAL MORTALITY)
effect of maternal smoking and gestational age, 8:43
effect of maternal smoking and other factors, 8:41
etiology of perinatal death in smokers vs. nonsmokers, 8:37
maternal smoking and, research needs, 8:76
maternal smoking levels and, 8:39-40

**NEOPLASMS**
(See also CARCINOGENESIS; LEUKEMIA; MESOTHELIOMA)
aryl hydrocarbon hydroxylase inducibility and smoking and, 5:57
cigar and pipe smoking and, summary of findings, 1:27-28
effect of smoking on mortality ratio, 2:38
induced by polonium-210 in Syrian hamsters, 14:61
induced by tobacco smoke in animals, 1:17
mortality ratio in cigar and pipe smokers, 13:20
nitrosamines in etiology of, 12:74
in progeny after maternal exposure to benzo(a)pyrene in mice, 8:67
smoking and, summary of findings, 1:15–17
smoking and asbestos exposure and, 7:11–13
smoking in etiology of, historical perspective, 5:9
Neoplasms, bronchial
See BRONCHIAL NEOPLASMS
Neoplasms, esophageal
See ESOPHAGEAL NEOPLASMS
Neoplasms, laryngeal
See LARYNGEAL NEOPLASMS
Neoplasms, lip
See LIP NEOPLASMS
Neoplasms, lung
See LUNG NEOPLASMS
Neoplasms, mouth
See MOUTH NEOPLASMS
Neoplasms, pancreatic
See PANCREATIC NEOPLASMS
Neoplasms, pharyngeal
See PHARYNGEAL NEOPLASMS
Neoplasms, oral
See ORAL NEOPLASMS
Neoplasms, tongue
See TONGUE NEOPLASMS
NEUROTICISM
(See also ANXIETY; STRESS)
cessation of smoking and, 18:17–18
maintenance of smoking and, 18:7–9
smoking characteristics and, 18:13
NICKEL
(See also METALS)
levels in tobacco smoke, 14:59
and smoking in lung neoplasm etiology, 5:20
NICOTINE
(See also ALKALOIDS, TOBACCO)
absorption by involuntary smoking, 11:24
addiction, 18:7–9, 18:12
in allergy induction, 10:22
in amniotic fluid after maternal injection in animals, 8:54
in atherosclerosis induction in animals, 4:16
cardiocirculatory diseases and, 14:79
carotid blood levels after oral administration, 14:86
central nervous system receptor sites, 16:18–19
dependence and, 14:97
effect of cigar smoke inhalation on absorption, 13:16–17
effect of fetal injection in utero in animals, 8:56
effect of maternal injection on fetus in animals, 8:54–57
effect of maternal injection on nursing kittens, 8:49
effect of maternal injection on offspring in rats, 8:10–11
effect of maternal injection on psychomotor function in newborn animals, 8:57
effect of self-administration on smoking habit, 15:12
effect of smoking characteristics on absorption, 14:87
effect on angina pectoris, 4:39
effect on antidiuretic hormone secretion, 12:37, 12:54
effect on arousal, 15:11
effect on arteries in rabbits, 4:56
effect on behavior in monkeys, 15:12
effect on behavior in rats, 15:11, 15:18
effect on birth weight in animals, 8:53
effect on blood lipid levels in animals, 4:61
effect on blood pressure and heart rate, 4:58, 14:87, 14:91
effect on cardiovascular system, 12:52–54, 14:89
effect on cardiovascular system in animals, 8:55–56
effect on cardiovascular system in animals with myocardial infarct, 4:45
effect on catecholamines in rats, 14:88
effect on central nervous system, 14:89
effect on cerebrovascular circulation, 4:50
effect on corticosteroid secretion, 12:40
effect on drug assays, 12:34
effect on enzyme activity, 12:27-28, 14:87
effect on enzyme activity in rat intestines, 12:76
effect on exercise induced angina pectoris, 4:47
effect on fetal and newborn central nervous system, 8:57
effect on fetal and newborn central nervous system in animals, 8:56
effect on fetus, research needs, 8:79
effect on fetus and breastfed infants of smoking mothers, 8:51
effect on free fatty acids, 12:40, 14:90
effect on gastric secretion in cats, 9:12-13
effect on gastric secretion in man, 9:13-14
effect on heart function in animals with coronary heart disease, 4:40
effect on hormones in monkeys, 10:90
effect on immunoglobulins, 6:31
effect on ischemia, 4:39
effect on lactation in cats, 8:49
effect on lactation in cows, 8:49
effect on lactation in rats, 8:49
effect on lung function, 14:90
effect on lymphocytes in mice, 10:19
effect on nitrosamine biosynthesis, 12:75
effect on pancreatic secretion in dogs, 5:53, 9:14-15
effect on patellar reflex, 14:92
effect on pharmacokinetics, 12:27-28
effect on psychomotor performance, 16:8
effect on pregnant rats, 8:10-11
effect on serum secretin levels, 9:14-15
effect on smoking habit, 15:7-8
effect on smoking habit, summary of findings, 1:30-32
effect on tolerance in rats, 15:16
effect on vitamin C levels in animals, 12:66
in establishing smoking habit, 15:9
excretion under stress, 16:8
induction of hyperglycemia in cats, 14:90
induction of peptic ulcer in cats, 9:12
induction of peptic ulcer in rats, 9:12
interactive effect with oxprenolol on blood pressure, 12:54
interactive effect with propranolol on cardiovascular system, 12:53
internal regulation in smokers, 16:13-14
in maintenance of smoking habit, 15:14
maternal-fetal exchange in animals, 8:54
metabolism in maternal and fetal liver in animals, 8:55
metabolism in smokers vs. nonsmokers, 15:9
methods of absorption, 14:80
myocardial infarct and, 4:20
pancreatic neoplasms and, 5:53
pharmacology in cessation of smoking, 14:94, 14:97
protonation and, 14:108
as reinforcer, 16:12, 16:18
relative molar potency in cigarette smoke, 14:96
role as hapten, 10:11
role in alteration of drug metabolism, 12:40
sales weighted average delivery in American cigarettes, 14:111
smoke dosimetry and, 14:75
structural formula, 14:46
summary of physiological effects, 1:30-31

NICOTINE CONTENT
(See also ALKALOID CONTENT)
in blood, effect of smoking cigarettes vs. little cigars, 14:87
in blood after oral administration, 14:86
in cigar vs. cigarette smoke, 13:11
in cigarette smoke, 14:45
in cigarettes, health characteristics and, 3:11
in cigarettes vs. little cigars, 14:44-45
in cow's milk after intramuscular injection, 8:49
decrease in modern cigarettes, A:19-20
effect on mortality, 2:22
filters and, 14:104
in milk of lactating smoking vs. nonsmoking mothers, 8:50-51
as smoke inhalation indicator, 14:75
in urine and plasma of smokers vs. non-smokers, 11:84
in urine as measure of tobacco usage, 15:29
in urine of smokers vs. non-smokers, 15:29
NICOTINE CHEWING GUM
in cessation of smoking, 19:16-17
in reduction of smoking, 16:8
NICOTINE-IN-SALIVA TEST
correlation with self-reported smoking, 17:24
NICOTINE METABOLISM
(See also METABOLISM)
degree of protonation in relation to pH, 14:86
distribution and clearance in rats, 14:79
effect of urinary pH on excretion, 14:92-93
enzymes and, 14:87
pathway, 14:93
rate of absorption, 14:92
NICOTINE METABOLITES
(See also COTININE; NORNICOTINE)
in cigarette smoke, 14:38-94
effect of urinary pH on excretion, 14:92
NICOTINE REDUCTION
in cigarettes in the United States, 14:44
effect on lung neoplasm mortality ratio, 5:15-16
methods, 14:114
in particulate phase of cigarette smoke, 14:108
NICOTINE TOXICITY
atherosclerosis and, 14:79
effect on heart, 14:78
effect on smoke inhalation dosimetry, 14:75
hypertension and, 14:79
NITRIC OXIDE
in blood of smokers vs. non-smokers, 14:80
effect on enzyme activity in rats, 14:81
NITRILES
levels in cigarette smoke, 14:40
NITROGEN COMPOUNDS
in cigarette smoke, 14:41
in soil, effect on tobacco leaf quality, 14:15-16
NITROGEN DIOXIDE
effect on antibody response to bacterial vaccines in mice, 12:59
effect on respiratory tract in rats, 14:81
NITROGEN OXIDES
absorption, 14:99
cardiovascular diseases and, 4:82
content in mainstream cigarette smoke, 14:39
NITROSAMINE CONTENT
in cigarette smoke, 14:30, 14:45
effect of curing and fermentation, 14:45
effect of homogenized leaf curing, 14:39
effect of smoking in enclosed spaces, 11:25
reduction in gas phase cigarette smoke, 14:107
reduction in particulate phase cigarette smoke, 14:112
in tobacco and tobacco smoke, 12:74
NITROSAMINES
(See also DIMETHYLNITROSAMINE)
aromatic practices and, 14:107
biosynthesis in smokers, 12:74-75
bladder neoplasms and, 5:47
in chewing tobacco, 14:45
effect of maternal injection on tracheal neoplasms in hamster offspring, 8:50
effect of nicotine on biosynthesis, 12:75
in esophageal neoplasm induction in animals, 5:44
in lung neoplasm induction in hamsters, 5:30
in neoplasm etiology, 12:74
in pancreatic neoplasm induction in hamsters, 5:51-53
precursors, 14:41
quantification by thermal energy analyzer, 14:11
in respiratory tract neoplasm induction in animals, 5:30
structural formulae, 14:46
NONSMMOKERS
(See also SMOKERS VS. NON-
SMOKE-SMOKERS)
absorption of tobacco smoke constituents, 11:6
annoyance caused by tobacco smoke, 11:25
annual probability of dying, 2:30-34
effect of involuntary smoking, 11:5, 11:15, 11:28

effect of involuntary smoking on

carboxyhemoglobin levels, 11:21, 11:23
effect of tobacco smoke, 11:25
median carboxyhemoglobin levels by
location, 11:23
nicotine absorption by involuntary
smoking, 11:24
perception of health status, 3:14-15
right, 16:19-20, 21:14, 21:18
typology, 18:13

NORNICOTINE
(See also NICOTINE METABO-
LITES)
relative molar potency in cigarette
smoke, 14:96
structural formula, 14:46

NORTRIPTYLINE
plasma concentrations in smokers vs.
nonsmokers, 12:39

NOSE IRRITATION

effect of smoking in enclosed spaces,
11:26

NURSES
role in cessation decision, 21:12,
21:14, 22:17
smoking habits, 22:12-14

NURSING HOMES
smoking policies, 22:20

OBESITY
(See also BODY WEIGHT)
cessation of smoking and, 12:67

OBSTRUCTIVE AIRWAY DISEASES
(See also BRONCHITIS; BRON-
CHOPULMONARY DISEASES;
CHRONIC OBSTRUCTIVE LUNG
DISEASE; EMPHYSEMA)
smoking in cotton workers and, 7:9-10
smoking in fire fighters and, 7:10-11
smoking in miners and, 7:9

OCCUPATIONAL DISEASES
(See also ASBESTOSIS; BYSSINO-
SIS; NEOPLASMS; POLYMER
FUME FEVER)
asbestosis, 7:11-13
byssinosis, 7:9
"Monday morning fever", 7:9
polymer fume fever, 7:5-6

OCCUPATIONAL EXPOSURE
bronchopulmonary diseases and, 1:19,
6:36, 7:13
interactive effect with smoking, sum-
mary of findings, 1:19-20
smoking and bladder neoplasms and,
5:47
smoking and pancreatic neoplasms
and, 5:47
and smoking in lung neoplasm etio-
logy, 5:27-29
smoking levels and health risk, 7:17

OCCUPATIONAL HAZARDS
alpha irradiation from radon, 7:14
aromatic amines, 7:16
asbestos, 7:11-13
beta radiation, 7:10
carbon monoxide, 7:8
chlorine, 7:10
chloromethyl ether, 7:15-16
dust, coal, 7:9
dust, cotton, 7:9
dust, gold, 7:15
effect of smoking and recommenda-
tions for research, 7:19
hydrogen cyanide, 7:7-8
rubber, 7:13

OCCUPATIONS
asbestos workers, 5:28, 7:11-13
battery factory workers, 7:15
benzene workers, 14:51
blast furnace workers, 7:8
blue- and white-collar workers, 7:17
bronchitis in smokers vs. nonsmokers
and, 6:39
chemists, 5:51
chlorine workers, 7:10
chloromethyl ether workers, 5:29,
7:15-16
cane workers, 7:16
cotton miners, 13:35
cotton workers, 7:9
electroplaters, 7:7
fire fighters, 7:10-11
gold miners, 7:15
industrial workers, 22:16-17, 22:19
insulation workers, 7:11
methylene chloride workers, 7:8-9
miners, 7:9
nickel workers, 5:28
rubber workers, 7:13
smoking prevalence rates and, 18:16, A:16
steelworkers, 7:8
telephone workers, 6:37
tobacco workers, female, 8:9
uranium miners, 5:28, 7:14, 12:90

OFFICE ON SMOKING AND HEALTH
information dissemination function, 23:27-28

Olefins
See ALKENES

ONTARIO PERINATAL MORTALITY STUDY, 8:38-39, 8.37, 8:39-42, 8:45

ORAL NEOPLASMS, 5:39-42
(See also LEUKOPLAKIA; LIP NEOPLASMS; MOUTH NEOPLASMS; TONGUE NEOPLASMS)
    alcohol consumption and smoking and, 5:40-41
    animal models, 6:41-42
    betel chewing in etiology of, 13:40-41
    cigar and pipe smoking and, 5:39
    induced by benzo(a)pyrene in hamsters, 5:42
    induced by dimethyl benzanthracene in hamsters, 5:42
    induced by methylcholanthrene in hamsters, 5:42
    mortality ratio in cigarette vs. cigar vs. pipe smokers, 13:21-23
    mortality ratio in smokers, 5:39-40
    smoking and, summary of findings, 1:17
    smoking in etiology of, 5:39-42
    snuff in etiology of, 13:39-40
    tobacco chewing and, 5:38-40
    tobacco chewing in etiology of, 13:40-41

ORALITY
    smoking habit and, 18:9

ORGANOTIN
    smoking and occupational exposure, 7:7

OSTEOPOROSIS
    smokers vs. nonsmokers, 12:67

OXPRENOLOL
    interactive effect with nicotine on blood pressure, 12:54

OXYGEN TENSION
    effect of maternal and fetal carboxyhemoglobin levels, 8:64

OXYGEN TRANSPORT
    effect of carbon monoxide in mother and fetus, 8:61

OXYHEMOGLOBIN SATURATION CURVES
    maternal and fetal, effect of carbon monoxide levels in blood, 8:62-63, 8:72

PANCREATIC NEOPLASMS
    animal models, 5:51-53
    correlation with bladder neoplasms, 5:47
diet and, 5:51
    effect of smoking levels on mortality and risk ratios, 5:50, 5:52
    effect of smoking and occupational exposure, 7:17
    induced by nitrosamines in hamsters, 5:51-53
    mortality and risk ratios in male vs. female smokers, 5:50-52
    naphthylamines and, 5:51
    nicotine and, 5:53
    occupational exposure and, 5:51
    smoking and, summary of findings, 1:17

PANCREATIC SECRETION
    effect of nicotine in animals and man, 9:14-15
    effect of nicotine in dogs, 5:53
    effect of smoking, 9:14-15

Paper, cigarette
    See CIGARETTE PAPER

Parental smoking
    See SMOKING, PARENTAL

PARKINSONISM
    smoking and, 8:43

PARTICULATE PHASE, CIGARETTE SMOKE
    (See also TARs, TOBACCO; TOTAL PARTICULATE MATTER)
    aromatic hydrocarbons reduction, 14:109
component levels, 15:6
definition, 14:35, 14:38
determination of tar levels, 14:43
levels of toxic compounds, 14:64–65
levels of metals, 14:59
nicotine reduction, 14:108
nitrosamines reduction, 14:112
ratio of constituents in main- vs. sidestream smoke, 11:6
polonium-210 reduction, 14:113
tar reduction methods, 14:110
toxicity reduction, 14:108
toxicity reduction methods, 14:114
Passive smoking
See INVOLUNTARY SMOKING
Peak expiratory flow measurements
See RESPIRATORY FUNCTION TESTS
PEER GROUPS
influence on cessation of smoking, 18:21
influence on drug abuse in adolescents, 18:14
influence on initiation of smoking, 16:5
influence on smoking habit in adolescents, 17:10, 17:14, 21:13–14
youth-to-youth antismoking programs, 20:9
PENTAZOCINE
dosage requirements in smokers vs. nonsmokers, 12:36
Peptic ulcer
See ULCER, PEPTIC
PERINATAL MORTALITY
(See also INFANT MORTALITY; MORTALITY RISK; NEONATAL MORTALITY)
effect of maternal smoking, summary of findings, 1:22
gestational age and risk in smoking vs. nonsmoking mothers, 8:43
maternal smoking in etiology of, 12:67
maternal smoking levels and, 8:39–40
PERIPHERAL VASCULAR DISEASE
animal models, 4:53
clinical and pathological features, 4:52
research needs, 4:54
risk factors, 4:52
smoking and, summary of findings, 1:14–15
smoking and, 4:53–54
smoking vs. nonsmoking diabetics, 4:53
PERSONALITY
(See also BEHAVIOR)
cessation of smoking and, 18:17–18, 18:21–22
effect on pharmacokinetics, 12:40–41
effect on success rates for cessation of smoking, 15:24
maintenance of smoking and, 18:5–10
maternal smoking and, 8:20
and recidivism, 19:31
and smoking habits in adolescents, 17:16
PESTICIDE RESIDUES
hydrazine formation, 14:41
reduction in tobacco, 14:61
structural formulae, 14:62
in tobacco leaf, 14:18
in tobacco smoke, 12:75
toxic effects in smokers, 12:75
pH
cigar vs. cigarette vs. pipe smoke, 13:15–16
PHAGOCYTOSIS
(See also MACROPHAGES, ALVEOLAR)
effect of tobacco smoke, 6:30–31
role in lung neoplasm etiology, 5:31
PHARMACISTS
antismoking advice to customers, 22:17
as role models, 22:8–9
smoking habits, 22:12
PHARMACODYNAMICS
(See also DRUG METABOLISM; PHARMACOLOGY)
absence of smoking effect, 12:37–39
clinical importance of smoking history in drug monitoring, 12:41–42
dexamethasone, effect of smoking, 12:97
diazepam, effect of smoking, 12:38
effect of smoking, 12:27–44
effect of smoking, summary of findings, 1:25–26
furosemide, effect of smoking, 12:37
propranolol, effect of smoking, 12:37
research needs, 12:44
smokers vs. nonsmokers, 12:36–37
PHARMACOKINETICS
(See also DRUG METABOLISM; PHARMACOLOGY)
absence of smoking effect, 12:37–39
antipyrine, in smokers vs. nonsmokers, 12:29-31
caffeine, effect of aromatic hydrocarbons in rats, 12:32-33
clinical importance of smoking history in drug monitoring, 12:41-42
effect of behavior and personality, 12:40-41
effect of marijuana, 12:42-43
effect of smoking, 12:27-44
effect of smoking, summary of findings, 1:25-36
ethanol, in smokers vs. nonsmokers, 12:39
glutethimide, in smokers vs. nonsmokers, 12:3
imipramine, effect of smoking, 12:33
meperidine, in smokers vs. nonsmokers, 12:39
nortriptyline, in smokers vs. nonsmokers, 12:39
pentazocine, in smokers vs. nonsmokers, 12:36
phenacetin, effect of cigarette smoke in rats, 12:29-29
phenacetin, in smokers vs. nonsmokers, 12:39-29
phenytoin, in smokers vs. nonsmokers, 12:38
research needs, 12:44
theophylline, effect of methylcholanthrene in rats, 12:32
theophylline, in smokers vs. nonsmokers, 12:31-32
warfarin, effect of benzo(a)pyrene in rats, 12:38
warfarin, in smokers vs. nonsmokers, 12:38

PHARMACOLOGY
(See also PHARMACODYNAMICS; PHARMACOKINETICS)
carbon monoxide in establishing smoking habit, 15:7
cigarette smoke, 14:85, 14:94, 14:97-99
dependence and tolerance in maintenance of smoking habit, 15:14
nicotine in establishing smoking habit, 15:5, 15:7-8
tar in establishing smoking habit, 15:7
tobacco alkaloids, 14:6

PHARYNGEAL NEOPLASMS
(See also RESPIRATORY TRACT NEOPLASMS)
alcohol consumption and smoking and, 5:40-41
mortality in cigar vs. cigarette vs. pipe smokers, 13:22-23
PHENACETIN
effect of cigarette smoke on pharmacokinetics in rats, 12:28-29
effect of methylcholanthrene on pharmacokinetics in rats, 12:28-29
pharmacokinetics in smokers vs. nonsmokers, 12:28-29

PHENOLS
in cigarette smoke condensate, 14:52
effect of filters, 14:54
effect on ciliary activity, 14:51
levels in cigar vs. cigarette smoke, 13:11-12
levels in smoke of filtered vs. nonfiltered cigarettes, 14:57
reduction of levels in gas phase cigarette smoke, 14:106
structural formulae, 14:56

PHENYL BUTAZONE
effect of smoking on pharmacokinetics, 12:33

PHENTOIN
pharmacokinetics in smokers vs. nonsmokers, 12:38

PHYSICAL ACTIVITY
(See also EXERCISE)
effect on coronary heart disease incidence in smokers, 4:28

PHYSICAL DEVELOPMENT
effect of maternal smoking on children, 1:21

PHYSICIAN VISITS
smokers vs. nonsmokers vs. ex-smokers, 3:15, 3:17

PHYSICIANS
as health educators, 22:15-16
role in cessation decision, 19:12-14, 21:11-12, 21:14, 22:19, 22:22
as role models, 22:6-8
in school antismoking programs, 26:9-10
smoking habits, 21:12, 22:9-14
Pipe
See SMOKE, PIPE; SMOKERS, PIPE; SMOKING, PIPE; TOBACCO, PIPE
PLACENTA
aryl hydrocarbon hydroxylase activity after maternal exposure to benz(a)pyrene in rats, 8:66
effect of maternal smoking, 8:69
effect of maternal smoking, research needs, 8:78
PLACENTA PREVIA
gestational age and risk in smoking vs. nonsmoking mothers, 8:44, 8:46
maternal smoking levels and, 8:39
maternal smoking levels and perinatal mortality, 8:40
PLACENTAL RATIO
effect of maternal smoking, 8:14-18
effect of oxygen availability, 8:17
in smokers vs. nonsmokers, 8:15-16, 8:18
POLONIUM-210
cardiovascular diseases and, 4:62
levels in cigarette smoke, 14:60
levels in smokers vs. nonsmokers, 12:74-75
neoplasm induction in Syrian hamsters, 14:61
reduction in particulate phase cigarette smoke, 14:113
in tissues of smokers vs. nonsmokers, 14:60-61
as tobacco contaminant, 14:29-21
POLYCYTHEMIA
smoking in etiology of, 12:83
POLYMER FUME FEVER
(See also OCCUPATIONAL DISEASES)
smoking and, 7:5-6
PREECLAMPSIA
maternal smoking and, research needs, 8:77
maternal smoking levels and, 8:42
PREGNANCY
(See also PRETERM DELIVERY)
accidental hemorrhage in smokers vs. nonsmokers, 8:39
cessation of smoking during, 22:16, 22:18, 22:23
complications, research needs, 8:76-77
smoking and abruptio placentae and placenta previa, 8:39
smoking and bleeding, 8:39
smoking and premature membrane rupture, 8:39
gestational age and premature membrane rupture in smokers vs. nonsmokers, 8:44, 8:46
smoking levels and abruptio placentae, bleeding, placenta previa and premature membrane rupture, 8:39-41
smoking levels and perinatal mortality, 8:40
PRETERM DELIVERY
effect of maternal smoking levels, 8:43
and infant mortality risk in smoking vs. nonsmoking mothers, 8:42
maternal smoking and, 1:22
in smoking vs. nonsmoking mothers, 8:42
PREVENTION OF SMOKING
(See also ANTISMOKING CAMPAIGNS; CESSATION OF SMOKING)
communication models, 17:11-12
recommendations for the future, 17:22-25
summary of methodologies and programs, 1:33-34
Swedish 25-year program, 17:21-22
youth programs, 17:6, 17:17-22
PROPOXYPHENE
clinical effect in smokers vs. nonsmokers, 12:36-37
PROPRANOLOL
interactive effect with cigarette smoke on airways, 12:54
interactive effect with nicotine on cardiovascular system, 12:33
interactive effect with smoking on cardiovascular system, 12:37
PROSTAGLANDINS
effect of cigarette smoke on metabolism in lungs in rabbits, 12:39
PROTEINS
effect of smoking on metabolism, 12:65-66
synthesis, role in enzyme induction, 12:21-22
PROTONATION
nicotine in relation to pH, 14:86
nicotine reduction and, 14:108

PSYCHOMOTOR PERFORMANCE
  effect of carbon monoxide, 11:28, 11:34
  nicotine deficit and, 16:8

PUBLIC HEALTH CIGARETTE SMOKING ACT, A:7

Pulmonary alveolar macrophages
  See MACROPHAGES, ALVEOLAR

Pulmonary clearance
  See CILIARY ACTIVITY; LUNG FUNCTION

Pyloric pressure
  effect of smoking, 9:16

RADIATION
  alpha exposure from radon as occupational hazard, 7:14
  beta exposure as occupational hazard, 7:10
  bladder neoplasms and smoking and, 12:90
  and cigarette tars in neoplasm induction in mice, 7:10
  laryngeal neoplasms and smoking and, 12:90
  and smoking in lung neoplasm etiology, 5:28
  synergistic effect with smoking on respiratory tract, 12:90

RADIOELEMENTS
  levels in tobacco and tobacco smoke, 14:90
  reduction in particulate phase cigarette smoke, 14:113
  as tobacco contaminants, 14:20-21

RADIUM-226
  levels in cigarette smoke, 14:90
  as tobacco contaminant, 14:20-21

Rapid smoking
  See AVERSIVE THERAPY

RECIDIVISM
  carboxyhemoglobin levels as measure of, 15:29-30
  cognitive and physiological factors, 16:18
  post-treatment followup, 19:8
  prevention, 19:30-31, 19:35
  rates in cessation programs, 21:15-17
  withdrawal state and, 16:18

Reconstituted tobacco sheet
  See TOBACCO SHEET

REFLEXES
  effect of nicotine, 14:92

Relative molar potency
  See MOLAR POTENCY

RELIGION
  church attendance and motivation for smoking, 18:11
  effects of beliefs on tobacco consumption, 18:24

RESPIRATORY FUNCTION TESTS
  (See also LUNG FUNCTION)
  in smokers vs. nonsmokers vs. ex-smokers, 6:14-16

RESPIRATORY SYMPTOMS
  in cigar and pipe smokers vs. non-smokers, 13:34
  in childhood and adult respiratory tract disease, 6:38-39
  in cigar vs. cigarette vs. pipe smokers, 13:30-37
  effect of air pollution in smokers vs. nonsmokers, 6:37
  effect of smoking, 6:7
  effect of smoking in children, 6:11-12
  rate of decline of FEV in smokers vs. nonsmokers and, 6:22
  in smokers vs. nonsmokers, 6:20
  smoking and, summary of findings, 1:18-19
  smoking and sex ratio, 6:20
  smoking levels and, 6:20
  in smoking vs. nonsmoking twins, 6:35

RESPIRATORY SYSTEM
  (See also LUNGS; TRACHEA)
  effect of cessation of smoking, 15:21
  effect of inhalation in cigarette and pipe smokers, 13:15-16
  effect of nitrogen dioxide in rats, 14:81
  effect of rapid smoking, 19:26
  synergistic effect of uranium and smoking, 12:90

RESPIRATORY TRACT DISEASES
  (See also LUNG DISEASES)
  cessation of smoking in patients, 12:18-19
  effect of involuntary smoking in children, 11:32
effect of parental smoking on incidence in children, 11:32-34
effect of smoking and history of childhood respiratory symptoms, 6:38-39
mass media preventive campaign, 21:10
smoking and, 6:7
smoking history of young adults and, 6:12
smoking in children and, 6:11-12
RESPIRATORY TRACT INFECTIONS
allergic predisposition and smoking, 10:22
effect of parental smoking on incidence in children, 10:12, 11:32
effect of passive smoking in infants, 8:45
effect of smoking on mortality, 2:41
in smokers vs. nonsmokers, 6:20
smoking levels and, 6:30
RESPIRATORY TRACT MUCOSA
effect of smoking, 10:14
RESPIRATORY TRACT NEOPLASMS
(See also LARYNGEAL NEOPLASMS; LUNG NEOPLASMS; PHARYNGEAL NEOPLASMS; TRACHEAL NEOPLASMS)
smoking in uranium miners and, 7:14
RNA
effect of methylcholangthrene on metabolism, 12:21-22
role in enzyme induction, 12:21-22
ROBERT WOOD JOHNSON FOUNDATION
Health Activities Project, 21:20
ROLE MODELS
(See also PARENTAL SMOKING; PEER GROUPS; SIBLING SMOKING; TEACHERS; HEALTH PROFESSIONALS)
in cessation of smoking, 18:21, 22:6-9
influence on smoking in adolescents, 17:11, 20:6, 21:11-14, 23:36
RUBBER
occupational hazards, 7:13
SALIVA
nicotine and thiocyanates in smokers vs. nonsmokers, 15:30
SAN DIEGO COMMUNITY LABORATORY
program description, 20:14-15, 21:25
SASKATOON SMOKING STUDY
description 20:11-12, 23:25
SATURATED FATS
in atherosclerosis induction in animals, 4:9
SCHICK SMOKING CONTROL CENTERS
cessation program, 21:16
SCHOOL HEALTH CURRICULUM PROJECT
community agency involvement, 23:15
curriculum development approach, 23:19
description, 20:18-22
evaluation, 17:19-20, 20:25
parental involvement, 21:19
teacher training, 23:21-23, 23:32
SCHOOL HEALTH EDUCATION STUDY
antismoking education component, 23:18
SCHOOL PROGRAMS
(See also names of individual programs)
antismoking education, 20:5-22
colleges, 21:9-11
curriculum theory, 23:16-22
effect on students' smoking habits, 17:15
influence on parents, 21:19-21
recommendations for the future, 23:36-39
smoking policies, 23:3-15
state health education laws, 23:5-7
teaching methods, 23:25-27
SECRETIN RELEASE
effect of nicotine, 9:14-15
effect of smoking, 9:15-16
SELF-REPORTS
(See also VERBAL REPORT)
carboxyhemoglobin levels as indicator of accuracy, 3:12
SENSORY DEPRIVATION
cessation of smoking and, 19:18-19
SERUM IMMUNOGLOBULIN LEVELS
effect of smoking, 10:18
SERUM PRECIPITINS
in smokers vs. nonsmokers, 10:11
SEVENTH DAY ADVENTISTS
5-Day Plan (cessation program), 19:10, 21:15-16

SEX RATIO
absenteeism and, 3:8, 3:13
adolescent smoking, 17:7, 17:13, 18:16, 21:25
bed disability in smokers vs. non-smokers, 3:12
bladder neoplasms in smokers, 5:45-47
cessation of smoking and, 3:18, 18:21
cessation of smoking and alcohol consumption, 18:20
cessation of smoking and personality, 18:17-18
chronic obstructive lung disease and, 6:7
consumption of cigarettes, cigars, snuff, pipe and chewing tobacco in the United States, 14:13
coronary heart disease morbidity ratios in smokers vs. nonsmokers vs. ex-smokers, 4:28-30
coronary heart disease mortality ratios in smokers vs. nonsmokers, 4:24
effect of less hazardous cigarettes on mortality, 2:24-25
heart conditions and, 3:19
high density lipoprotein levels in smokers vs. nonsmokers, 4:61-62
laryngeal neoplasm risk in smokers and ex-smokers, 5:33, 5:35-36
lung function, 8:21-22
lung function in ex-smokers, 6:22
lung neoplasm mortality ratio in low tar and nicotine cigarette smokers, 5:16-17
lung neoplasm mortality ratio in smokers, 5:11-12
lung neoplasm risk in filtered vs. unfiltered cigarette smokers, 5:16, 5:18-19
pancreatic neoplasm mortality and risk ratios in smokers, 5:50-52
prevalence of acute conditions in smokers vs. nonsmokers, 3:9
prevalence of chronic conditions in smokers vs. nonsmokers, 3:7
prevalence of chronic obstructive pulmonary disease, 6:20
recidivism and, 19:31

SMOKING AND RESPIRATORY SYMPTOMS, 6:20
smoking and respiratory symptoms in children, 6:11-12
smoking characteristics, 5:21, 5:23
smoking habit and neuroticism, 18:8
smoking habit and socioeconomic status, 18:16
smoking habit in the United States, 5:19-21
smoking in blue- and white-collar workers, 7:17
smoking levels and lung pathology, 6:27
snuff users in the United States, 13:10
Teenage Self Test scores, 20:22
tobacco chewers in the United States, 13:10

SIBLING SMOKING
adolescents, 17:14
maintenance of smoking and, 18:15

SLEEP
deprived vs. nondeprived smokers, 15:11

SMALL AIRWAYS FUNCTION
(See also RESPIRATORY FUNCTION TESTS)
chronic obstructive lung disease and, 6:11
effect of smoking levels, 6:13-19
pathological lesions of small airways and, 6:18-19
screening methods for individuals at high risk for chronic obstructive lung disease, 6:12
in smokers vs. nonsmokers, 6:13
in smokers vs. nonsmokers vs. ex-smokers, 6:14-16

SMOKE, CIGAR
(See also SMOKERS, CIGAR;
SMOKING, CIGAR; TOBACCO, CIGAR)
ammonia content, 14:99
aromatic hydrocarbon content, 13:11-12
carbon monoxide content, 13:12, 14:88, 14:104
chemical analysis, 13:11-13
ciliotoxicity, 13:36-37
effect of inhalation on respiratory tract, 13:15-16
pH, 13:15-16
phenol content, 13:12

SMOKE, CIGARETTE
(See also SMOKERS; SMOKING; TOBACCO, CIGARETTE)
alcohol content, 14:42
alkane content, 14:48
amine content, 14:41
aldehyde content, 14:42
aromatic hydrocarbon content, 14:41-42
benzene compound content, 14:49
carcinogenic PAH activity, 14:54
chemical composition percent distribution, 14:35
constituents, and biological response, 14:35
constituents, research recommendations, 14:120
effect of cigarette manufacturing on constituents, 14:28-30
effect of constituents on enzyme activity, 12:7
effect of static burning temperature, 14:36
effect on antibody response in mice, 12:39
effect on central nervous system, 15:11
effect on immunoglobulins, 6:31-32
effect on lung function, 14:90
effect on macrophages, 6:29-30
effect on mucociliary system, 6:32-33
effect on phagocytic activity of alveolar macrophages, 10:17
effect on phenacetin pharmacokinetics in rats, 12:25-29
effect on prostaglandin F-2a metabolism in lungs in rabbits, 12:39
effect on systemic humoral immunity in mice, 10:18
free fatty acid levels, 14:55
heterocyclic compounds, 14:52, 14:57
hydrazine levels, 14:41
ketone levels, 14:42
naphthalene levels, 14:51
nickel levels, 14:59
nitric oxide levels, effect on blood pressure, 14:37
nitric oxide metabolites, 14:39-94
nitrile levels, 14:40

SMOKE, CIGARETTE MAINSTREAM
(See also SMOKE STREAMS)
alkane content, 14:48
amine content, 14:47
arsenic content, 14:39
arsenic content, 14:59
cadmium content, 14:60
catechol content, 14:53
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
free fatty acid levels, 14:55
heterocyclic compounds, 14:52, 14:57
hydrazine levels, 14:41
ketone levels, 14:42
nitric oxide levels, effect on blood pressure, 14:37
nitric oxide metabolites, 14:39-94
nitrile levels, 14:40

nitrogen compound levels, 14:41
nitrosamine precursors, 14:41
nonvolatile nitrosamine levels, 14:45
pharmaceutical, 14:85, 15:5
phenol levels, 14:57
physical and chemical nature, 14:35
polynuclear aromatic hydrocarbon indicators, 14:111
polynuclear aromatic hydrocarbons, 14:51
radioelements, 14:60
reaction mechanisms, 14:9
reduction of toxicity, 14:104, 14:108
relative molar potency of alkaloids, 14:96
retention in buccal cavity and respiratory tract, 12:7
standard smoking conditions for analysis, 14:35
structural formulae of pesticide residues, 14:62
sulfur compounds levels, 14:40
summary of gas and particulate phase constituents, 1:29-30
summary of toxic and carcinogenic constituents, 1:30
toxicity reduction methods, 14:114
weakly acidic heterocyclic compounds structural formulae, 14:36

SMOKE, CIGARETTE SIDESTREAM
(See also SMOKE STREAMS)
alkane content, 14:48
amine content, 14:47
cadmium content, 14:60
catechol content, 14:53
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
detoxification and, 14:105
free fatty acid levels, 14:55
heterocyclic compounds, 14:52, 14:57
hydrazine levels, 14:41
ketone levels, 14:42
nitric oxide levels, effect on blood pressure, 14:37
nitric oxide metabolites, 14:39-94
nitrile levels, 14:40
nicotine content, 14:45

tar content, 14:44

temperature profile, 14:36

Smoke exposure

See SMOKE INHALATION

SMOKE CONDENSATES

(See also SMOKE, TOBACCO; TARS, TOBACCO)

benzo(a)pyrene content, 14:112
carcinogenicity, 13:30-32
carcinogenicity of experimental cigarettes in mice, 14:30
cigar, alkaloid content, 13:11
cigar, aromatic hydrocarbon content, 13:11-12
cigar, nicotine content, 13:12
cigar, phenol content, 13:11-12
effect of cigarette manufacturing on composition, 14:28-30
effect on antiprotease activity in vitro, 6:28
effect on elastase release from lungs in rats, 6:29
effect on enzyme release from polymorphonuclear leukocytes, 6:28
genotoxic content, 14:52
role of cigarette manufacturers in control of constituents, 14:9

SMOKE INHALATION

(See also SMOKING)
effect on cigar and pipe smoke pH, 13:15-16
effect of switching tobacco products on patterns, 13:18-19
effect on arterioles in dogs, 4:18
effect on blood pressure in cats, 14:77
effect on carboxyhemoglobin levels in cigar and pipe smokers, 13:18
effect on cigarette smoke retention in buccal cavity, 12:7
effect on coronary heart disease mortality ratios, 4:37
effect on enzymes in dogs, 14:78
effect on exercise tolerance in rats, 14:77
effect on hemodynamics in dogs, 14:78

effect on leukocyte count, 8:82
effect on lung neoplasm mortality ratio, 5:14-15
effect on lung neoplasm mortality ratio in women, 5:21-22
effect on lungs in dogs, 14:76
effect on lungs in monkeys, 14:76
effect on mortality, 2:20-21
effect on mortality in cigar and pipe smokers, 13:18
effect on mortality ratio, 2:22-24
effect on mortality ratio in women, 2:20-27
effect on myocardial infarct morbidity and mortality, 4:35
effect on nicotine absorption in cigar smokers, 13:16-17
effect on pregnant rats, 8:10-11
effect on respiratory system in cigar and pipe smokers, 13:15-16
effect on tolerance in dogs, 15:16
exercise in dogs and, 14:78
exposure methodology, 14:72-74

in laryngeal neoplasm induction in hamsters, 5:34

males vs. females, 5:21, 5:23
maternal, effect on mother and fetus in sheep, 8:53
maternal, effect on offspring in rats, 8:10-11
in myocardial infarct induction in dogs, 14:77

patterns in cigar vs. cigarette vs. pipe smokers in Great Britain, 13:18-19
patterns in the United States, 2:33

SMOKE, PIPE

(See also SMOKERS, PIPE; SMOKING, PIPE; TOBACCO, PIPE)

aromatic hydrocarbon content, 13:11-12
pH, 13:15-16

SMOKE STREAMS

(See also SMOKE, CIGARETTE MAINSTREAM; SMOKE, CIGARETTE SIDESTREAM)

carbon monoxide content, 11:15
involuntary smoking and, 11:5
ratio of constituents in main vs. sidestream smoke, 11:6

SMOKE WATCHERS

cessation program, 21:16

SMOKENDERS

cessation program, 21:16
followup evaluation, 19:11
SMOKE, TOBACCO
(See also SMOKE, CIGAR; SMOKE, CIGARETTE; SMOKE, PIPE; SMOKING)
absorption of constituents by non-smokers, 11:6, 11:15
in allergy etiology, 10:23-24
amine and nitrosamine content, 12:74
antigens, identification of, 10:11
carcinogens, clastogenic agents and tumor promoters in gas phase, 5:54-55
carcinogens, cocarcinogens and tumor promoters in particulate phase, 5:54-57
constituents, correlation with tobacco leaf characteristics, 14:24
effect of exposure in allergic children and adults, 10:14, 10:21
effect on alveolar macrophages, 6:30-31, 10:15-16
effect on blood lipid levels in animals, 4:61
effect on cardiovascular system in animals with myocardial infarct, 4:45
effect on cellular and humoral immunity, 6:30-31
effect on ciliary function, 10:14-15
effect on enzyme activity, 12:27-28, 12:75-76
effect on enzyme systems, 10:16
effect on fetal weight and birth weight in animals, 8:52
effect on fetal weight and maternal food intake in rats, 8:52-53
effect on fetus, research needs, 8:79
effect on immune system, 10:5, 10:17
effect on lymphocytes in mice, 10:19
effect on metabolism of food constituents and additives, 12:75-76
effect on nonsmokers, 11:25
effect on pre-existing allergies, 10:13
effect on pregnant animals, 8:52
effect on rat fetus, 8:53
effect on tracheobronchial clearance in dogs, 10:15
eye irritation and, 10:21
heterocyclic compound carcinogens structural formulae, 14:55
measurement of constituents in enclosed spaces, 11:7-14
measurement of constituents under natural conditions, 11:16-20
metal levels, 14:58-59
in neoplasm induction in animals, 1:17
nickel levels, 14:59
pesticide residues, 12:75
radioelement levels, 14:60
skin test reactions, 10:13
SMOKERS
(See also SMOKERS, CIGAR; SMOKERS, PIPE)
B and T cell count and ratio, 10:19
granular leukocyte levels, 10:20
SMOKERS, CIGAR
(See also SMOKE, CIGAR; SMOKING, CIGAR; TOBACCO, CIGAR)
blood cholesterol levels, 4:61
bronchitis and emphysema mortality, 13:34
cardiovascular disease mortality ratio, 13:33
chronic obstructive pulmonary disease mortality ratio, 13:35
coronary heart disease mortality ratio, 4:22-23
effect of inhalation on mortality, 13:18
esophageal neoplasm mortality, 13:24-25
esophageal neoplasm mortality ratio, 5:43
inhalation patterns in Great Britain, 13:18
leukocyte count, 12:81
lung neoplasm mortality rates, 5:23
lung neoplasm mortality ratio, 13:25-26
mortality, 13:13-14
myocardial infarct morbidity and mortality, 4:35
oral neoplasm mortality ratio, 13:21
relative risk ratio for lip neoplasms, 13:22
relative risk ratio for lung neoplasms, 13:29-30
respiratory symptoms, 13:34
thrombosis mortality rates, 4:59
in the United States, 13:9
SMOKERS, PIPE
(See also SMOKE, PIPE; SMOK-ING, PIPE; TOBACCO, PIPE)
blood cholesterol levels, 4:61
bronchitis and emphysema mortality,
13:34
cardiovascular disease mortality ratio,
13:33
chronic obstructive pulmonary disease
mortality ratio, 13:35
coronary heart disease mortality ratio,
4:22-23
effect of inhalation on mortality,
13:18
effect of inhalation on respiratory tract,
13:25
esophageal neoplasm mortality,
13:24-25
esophageal neoplasm mortality ratio,
3:28
inhalation patterns in Great Britain,
13:24
leukocyte count, 12:81
lung neoplasm mortality rates, 5:23
lung neoplasm mortality ratio, 13:26-28
mortality, 13:13-14
myocardial infarct morbidity and mortality, 4:35
oral neoplasm mortality ratio, 13:21
relative risk ratio for lip neoplasms,
13:22
relative risk ratio for lung neoplasms, 13:29-30
respiratory symptoms, 13:34
thrombosis mortality rates, 4:19
in the United States, 13:9
SMOKERS VS. NONSMOKERS
(See also NONSMOKERS)
abruptio placentae, placenta previa,
and bleeding during pregnancy,
8:39
absenteeism, 3:8, 3:10, 3:13
accidental hemorrhage in pregnancy,
8:39
activity limitation, 3:13-14
acute conditions, 3:6
air pollution and chronic obstructive lung disease, 6:96
air pollution and lung pathology, 6:96
alcohol consumption and drug use, 12:41
alpha-1-antitrypsin deficiency and emphysema, 6:34
alveolar macrophage migration, 6:31
angina pectoris morbidity ratios, 4:22-23
annual probability of dying, 2:30-31
antibody response to viral vaccines, 12:58-60
antipyrine pharmacokinetics, 12:29-31
anxiety levels, 16:7-8
Arthus skin test characteristics, 10:10
asphyxia in infants of, 8:69
atherosclerosis, 4:10-12, 4:14-16
B and T lymphocytes, 6:31
bed disability, 3:12
bilirubin levels, 12:34
birth weight of infants of, 8:11,
8:14-17, 8:20-21
bladder neoplasm mortality ratio,
5:45-46
blood calcium levels, 12:84
blood cholesterol levels, 4:61-62
blood circulation, 15:12-13
blood coagulation, 12:84-86
blood glucose levels, 12:84
blood lipid levels, 12:83-84
blood pressure, 12:57
blood protein levels, 12:84
breast feeding, 8:48
bronchitis in gold miners, 7:15
bronchitis prevalence by occupations, 6:39
carboxyhemoglobin levels and carbon monoxide occupational exposure, 7:8
carboxyhemoglobin levels in infants of, 8:69
carcinoembryonic antigen levels, 12:61-62
cardiovascular disease mortality ratios in Japan, 4:21, 4:34-35
cerebrovascular disease mortality rates and ratios in males vs. females, 4:51
chronic obstructive lung disease and mortality, 6:9-10
ciliary function, 10:15
clinical effects of propoxyphene, 12:36-37
clinical effects of selected drugs, 12:36-37
coronary heart disease morbidity ratios, 4:27-33, 4:36-37
coronary heart disease mortality ratios, 4:22-26, 4:36-37
definition, 23:24
drug use patterns, 18:13-15
duration of gestation, 8:18
effect of behavior and personality on pharmacokinetics, 12:40-41
elastase release from macrophages, 6:30
emphysema, 6:25-26
emphysema and lung pathology, 6:23-24
erthrocyte parameters, 12:8-33
esophageal neoplasm mortality ratio, 5:42-43
ethanol pharmacokinetics, 12:39
etiology of fetal and neonatal death, 8:38
tiology of perinatal death, 8:36
tiology of stillbirth, 8:37
fibrosis in asbestos workers, 7:12
gastric secretion in, 9:13
gestational age and infant mortality, 8:46, 8:45

gestational age and risk for abruptio placentae, placenta previa and premature membrane rupture,
8:44, 8:46
gestational age and risk for preterm delivery, 8:44
gestational age at birth of infants of, 8:43
glutethimide pharmacokinetics, 12:33

growth and development of children of, 8:21-23
heart conditions, 3:16-17, 3:19
head circumference in infants of, 8:20-21
hematocrit in infants of, 8:69
high density lipoprotein levels in males vs. females, 4:61-62
histologic changes in esophagus, 5:44
hospitalization, 3:14-16
hyaline thickening in small arteries and arterioles in myocardium, 4:16
hypertension, 4:57
immunoglobulin containing cell counts in lobar bronchi, 10:17
immunoglobulin levels, 6:31-32
infant mortality, 8:27, 8:34
infant mortality risk, 8:31
infarct mortality risk in black vs. white mothers, 8:30
job accident rates, 7:15
kidney, liver, and lung weights, 12:9
kidney neoplasm mortality and risk ratios, 5:48-49
lactation, 8:48
laryngeal neoplasm mortality ratio, 5:32-33
learning, 15:19
leukocyte count, 2:79-82
level of well-being, 3:18
long-term study of children of, 8:22-23
lung diseases in rubber workers, 7:13
lung function, 6:21
lung function after cadmium exposure, 7:15
lung function in black vs. white vs. oriental men and women, 6:21
lung function in chlorine workers, 7:10
lung function in cotton workers, 7:9
lung function in miners, 7:9
lung neoplasm mortality and asbestos exposure, 7:11
lung neoplasm mortality in twins, 5:23
lung neoplasm mortality ratio in males vs. females, 5:11-12
lung neoplasm mortality ratio in women, 5:20-22
lung neoplasm risk in asbestos factory workers, 7:11-12
lung neoplasm risk in insulation workers, 7:11
lung neoplasms in chloromethyl ether workers, 7:16
lung neoplasms in uranium miners, 7:14
lung pathology, 6:24-27
lung pathology in sudden death victims, 6:18
macrophage count and ultrastructure, 10:16
macrophages in bronchopulmonary lavage fluid, 6:29
maternal weight gain and fetal growth, 8:24-25
meperidine clearance, 12:39
mortality in twins, 2:42
mortality rates, 2:15
myocardial infarct in women, 12:52
myocardial infarct morbidity and mortality, 4:35-36
neonatal mortality, 8:40
nicotine and cotinine content in urine, 11:24
nicotine content in plasma, 11:24
nicotine content of breast milk in lactating mothers, 8:51
nitric oxide levels, 14:60
nicotine metabolism, 15:16, 15:9
nortriptyline pharmacokinetics, 12:39
obstructive airway diseases in miners, 7:9
oral neoplasm mortality ratio, 5:39-40
osteoporosis, 12:67
pancreatic neoplasm mortality and risk ratios, 5:50-52
pentazocine dosage requirements, 12:36
peptic ulcer healing, 9:9-10
peptic ulcer incidence, 9:5-6
peptic ulcer mortality rates, 9:11
peptic ulcer prevalence, 6:7-8
peptic ulcer prevalence ratios in six countries, 9:8
peptic ulcer size and recurrence, 9:9
perception of health status, 3:14-15
perinatal mortality, 8:35, 8:40
premarital mortality and maternal age, parity, and education, 8:33
premarital mortality risk for infants of, 8:32
peripheral vascular disease in diabetes, 4:38
personality, 18:5-10
phagocytic activity of alveolar macrophages, 10:17
phenacetin pharmacokinetics, 12:28-29
phenytoin pharmacokinetics, 12:38
physician visits, 3:14, 3:17
placental changes, 8:69
placental ratios, 8:18
polonium-210 levels in tissues, 10:60-61
preeclampsia and toxemia in pregnancy, 8:42
pregnancy weight gain and fetal growth, 8:24
premature membrane rupture during pregnancy, 8:39
preterm delivery and infant mortality risk, 8:42
prevalence of acute conditions, 3:9
prevalence of chronic conditions, 3:7
prognosis following vascular grafting, 4:53
protease activity of macrophages, 6:29
proteinuria after cadmium exposure, 7:15
rate of decline of FEV and respiratory symptoms, 6:22
respiratory symptoms in twins, 6:35
respiratory tract diseases in young adults, 6:12
respiratory tract infections, 6:20
respiratory tract neoplasms in uranium miners, 7:14
response to diagnostic tests, 12:79
risk of low birth weight in infants of, 8:13
serum albumin, uric acid, and creatinine concentration, 12:40, 12:84
serum precipitins in, 10:11
skin test reactions to tobacco leaf nictation, 10:15
small airways function, 6:13-16
socioeconomic status and chronic obstructive lung diseases, 6:38
spontaneous abortion, 8:30-32
stillbirth incidence, 8:36
sudden cardiac death, 4:43-44
sudden infant death syndrome in infants, 8:45
T cell counts, 10:19
theophylline pharmacokinetics, 12:31-32
thiocyanate levels in saliva, 15:20
thiocyanates in plasma, 7:7
thiocyanates in urine, 7:7
thrombosis mortality rates, 4:59
tolerance to cigarette smoke, 15:16-17
trace metal levels, 12:73-74
tryptophan metabolism, 12:67
umbilical artery changes, 8:69
vitamin B12 levels in pregnancy, 8:73
vitamin C levels in breast milk of lactating mothers, 8:52
vitamin C levels in pregnancy, 8:74
vitamin C levels in serum, 12:34
warfarin metabolism, 12:35